冠状动脉粥样硬化性心脏病患者红细胞流变性特征在红花注射液干预后的表现  

Characteristics of erythrocyte rheology in patients with coronary atherosclerotic heart disease after Honghua injection

作　　者：李俊杰[1] 姜丽杰[2] 侯亚利[3] 梁海峰[4] 赵自刚[1] 

机构地区：[1]河北北方学院病理生理教研室,河北省张家口市075000 [2]张家口教育学院基础医学部,河北省张家口市075000 [3]河北北方学院附属第一医院检验科,河北省张家口市075000 [4]河北北方学院附属第一医院心血管内科,河北省张家口市075000

出　　处：《中国组织工程研究与临床康复》2007年第20期3912-3915,共4页Journal of Clinical Rehabilitative Tissue Engineering Research

基　　金：河北省科技攻关项目(052761690)~~

摘　　要：目的:经红花注射液干预后,观察冠状动脉粥样性心脏病患者红细胞电泳指标及红细胞变形性的变化。方法:①选取2001-02/2002-10河北北方学院附属第一医院心内科住院的冠状动脉粥样硬化性心脏病患者50例作为冠状动脉粥样硬化性心脏病组,男31例,女19例,平均年龄(43.9±5.6)岁,对本实验知情同意,均自愿参加。②纳入标准:经心电图、超声心动图证实有典型心绞痛、心绞痛不典型或陈旧性心肌梗死史,由专科医师确诊冠脉造影狭窄率≥50%;治疗前均未进行降脂、利尿剂、促血尿酸排泄药、阿司匹林及肝素(包括低分子肝素钠)治疗;无肝肾疾病、内分泌系统疾病。③以30例自愿体检受试的健康学生及医务人员作为正常对照组,男女各15例,平均年龄(35.4±7.4)岁。两组间年龄、性别差异无显著性意义。④“得强”红花注射液,主要成分为红花黄色素,由太原华卫药业有限公司生产,批号010302。⑤冠状动脉粥样硬化性心脏病组取红花注射液6.0～8.0mL,溶于500mL葡萄糖注射液中,静点,1次/d,15d为1个疗程,共1个疗程。正常对照组未给予任何干预措施。⑥治疗前后两组空腹抽取肘静脉血5mL,应用红细胞变形分析仪检测红细胞电泳指标及红细胞变形性的变化。结果:50例冠状动脉粥样硬化性心脏病患者均进入结果分析。①治疗前后红细胞电泳指标的变化:与正常对照组比较,冠状动脉粥样硬化性心脏病组治疗前红细胞电泳时间显著延长,红细胞电泳长度与红细胞迁移率显著降低(t=3.198～6.963,P均<0.01);治疗后红细胞电泳时间缩短,红细胞电泳长度与红细胞迁移率增加(t=2.212～3.672,P<0.05或0.01),但仍与正常对照组存在显著性差异(t=1.700～4.792,P<0.05或0.01)。②治疗前后不同切变率下红细胞变形性变化:与正常对照组比较,冠状动脉粥样硬化性心脏病组治疗前在300S-1,230S-1,115S-1切变率下的红细胞变�AIM： To observe the changes of erythrocyte electrophoresis indexes and deformability in patients with coronary atherosclerotic heart disease （CAHD） after Honghua injection intervention. METHODS： （1）Totally 50 inpatients with CAHD which were diagnosed by specialist as CAHD group in Department of Cardiology of First Affiliated Hospital of Hebei North University from February 2001 to October 2002, in which there were 31 males and 19 females with an average age of （43.9±5.6） years, and all patients knew the inside treatment and agreed with the attendance. （2）inclusive criteria： The CAHD patients were diagnosed base on representative angina, or no representative angina and timewom myocardial infarction by electrocardiogram and ultrasonic electrocardiograph; straitness rate of coronary artery was at least 50% by diplomate. There was no treatment of lower fat, hydragogue, blood uric acid excretion drug, aspirin and heparin （including low molecular heparin） before treatment with Honghua injection, and no disease of liver, kidney and endocrine system in them.（3）Totally 30 healthy students and medical staffs were as normal control group, and in which there were 15 males and 15 females with an average age of （35.4±7.4） years. The age and sex were no statistics significance between the two groups. （4）The main ingredients was saffor yellow in Honghua injection of ＂Deqiang＂, provided by Taiyuan Huawei Pharmaceutical Co., Ltd., with the batch number of 010302. （5）The patients with CAHD were treated by Honghua injection for one therapy period, a period of therapy Was about 15 days and the 6.0- 8.0 mL Honghua injection mixed to 500 mL glucose injection each time. Normal control group did not receive any intervention. （6）The ancon vein blood was taken out for 5 mL to measure the changes of electrophoresis and deformability of erythrocytes before and after treatment in the two groups by analysis apparatus of erythrocytes deformability. RESULTS： Totally 50 patients with CAHD were

关 键 词：冠状动脉疾病/中药疗法 红花/治疗应用 电泳 变形性 红细胞 

分 类 号：R053.1[医药卫生]